PPARA and metabolic dysfunction-associated steatohepatitis: Saroglitazar is a dual PPAR‐α/γ agonist which has undergone various testing in rodent models and shows promise for human subjects with NASH and diabetes.93, 94 The EVIDENCES IV phase‐II clinical trial (NCT03061721) is currently being run as a randomized, placebo‐controlled study in 104 patients.